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disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named
LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network).
Methods: Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers. Genetic testing of the
appropriate candidate genes at one of six molecular diagnostic laboratories serving as nationwide DNA diagnostic centers.
Results and conclusions: From 2012 to October 2016, available biochemical and clinical information of 3480 subjects with familial
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primary dyslipidemias in Italy.
 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Dyslipidemias; Genetic testing; National network* Corresponding author. Dipartimento Biomedico di Medicina Interna e
Specialistica (Di.Bi.M.I.S), University of Palermo, Via del Vespro 141, I-
90127 Palermo, Italy.
E-mail address: maurizio.averna@unipa.it (M. Averna).
1 Members of the LIPIGEN Steering Committee.
2 Please see Appendix section for Members of the LIPIGEN Steering
Committee.
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.07.001
1567-5688/ 2017 The Authors. Published by Elsevier Ireland Ltd. This is an ope
org/licenses/by-nc-nd/4.0/).1. Introduction
Primary or monogenic dyslipidemias are a heteroge-
neous group of disorders characterized by abnormal levels
of circulating cholesterol, triglycerides or a combination
of the two due to single gene defects. Monogenicn access article under the CC BY-NC-ND license (http://creativecommons.
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density lipoprotein-cholesterol (LDL-C) levels and very
high risk of premature atherosclerotic disease; they are
caused by mutations in genes involved in the receptor-
mediated uptake of LDL-C by the LDL receptor (LDLR)
in hepatocytes [1]. Primary or genetic forms of hyper-
triglyceridemia (HTG) with a monogenic etiology include
mostly severe forms characterized by the accumulation in
plasma of TG-rich lipoproteins (chylomicrons, VLDL and
remnant lipoproteins) [2] and an increased risk of devel-
oping recurrent episodes of pancreatitis [3].
Despite substantial progresses in genetic testing and
counseling in addition to novel treatment opportunities,
primary dyslipidemias remain largely underdiagnosed and
undertreated in Western countries, including Italy [1]. The
development of nationwide clinical and genetic screening
programs may improve early identification and clinical
management through lifestyle modification or evidence-
based pharmacological intervention in order to reduce
risk of clinical endpoints, as well as promote genetic
counseling and guide efficacious health policy-making.
2. The model of the National FH screening program in
the Netherlands
In 1994 the Dutch government recognized the burden of
familial hypercholesterolemia (FH) on public health and
this prompted the development of a national Program
aimed at Identification of Persons with Inherited Hyper-
cholesterolemia (in Dutch: StOEH). The first step was to
inform all specialists in vascular medicine, cardiology and
endocrinology in the Netherlands of the screening program
in order to encourage the referral of patients with suspected
FH. In a later stage, general practitioners were also
involved in this process through direct mail, articles and
specific campaigns. A questionnaire was used to collect
information on medical history; blood samples were drawn
to determine lipid profiles and a screening program based
on a genetic cascade testing approach was developed and
implemented. Patients with clinical suspicion of FH were
referred to the StOEH and genetically tested for the pres-
ence of mutations in the candidate genes [1] at the
molecular diagnostic laboratory of the Academic Medical
Center (AMC) in Amsterdam, serving as a nationwide
DNA diagnostic center. Furthermore, if an FH causing
mutation was found in an index patient, the first-degree
relatives were contacted to be tested for the mutation of
the index patient as well. In turn, if the mutation was
identified in one of the first-degree relatives, the first-degree
relatives were then also offered to participate. This cascade
process stops in that branch of the family when the index-
mutation was not found in a tested subject. All participants
were informed of the DNA test result by letter and carriers
of an FH mutation were encouraged to contact a specialist
or their general practitioner to discuss initiation of lipid
lowering therapy.By the beginning of 2014, more than 60,000 subjects
had undergone genetic testing for FH in the Netherlands
[4]. The performance of the screening program was initially
evaluated after five years showing a participation rate over
90%. Only 39% of FH patients were treated with a statin at
time of screening, but this proportion increased to 93% in
the first year after the diagnosis of FH was made [5],
underlining that cascade testing approach may effectively
allow to identify those patients that require lipid-lowering
treatment (LLT) to prevent coronary heart disease (CHD)
as early as possible.
In fact, in line with coronary heart disease (CHD)
mortality rates reported in heterozygous FH (HeFH)
patients from the UK [6], the risk for CHD was increased
by almost four-fold in HeFH patients in the Netherlands [7]
compared to unaffected relatives.
Yet, of the expected 66,800 HeFH patients in the
Netherlands based on the estimated prevalence of HeFH of
1:250 [6], only 38.6% were diagnosed after 20 years of
screening, underlying that policy makers and health care
professionals need to be made more strongly aware of the
urgency of identification of FH patients.
Together with clinical improvements for individuals
diagnosed with FH, the Dutch screening program has also
improved scientific knowledge on this disorder. For
example, it has been recently shown that the prevalence of
type 2 diabetes mellitus (T2DM) is decreased in FH
patients, linking the LDL-R mediated cholesterol uptake to
pancreatic beta cell dysfunction in humans [8]. Moreover,
the registry allowed to evaluate in a prospective way the
proportion of FH patients reaching their treatment target
[9], and the awareness of the presence of the disease may
help in choosing better treatment options or in promoting
motivation of FH patients to participate in clinical trials for
innovative treatments.
3. The Italian national network
The Italian Atherosclerosis Society (SISA) proposed in
2009 the establishment through its scientific Foundation of
a Network aimed at facilitating the clinical and genetic
diagnosis of genetic dyslipidemias, named LIPIGEN
(LIpid TransPort Disorders Italian GEnetic Network). The
network consists of about forty clinical centers with a long
lasting experience in identifying and managing patients
with primary dyslipidemias including pediatric and LDL
apheresis institutions located throughout the country
(Fig. 1). The structure of LIPIGEN is based on a close
interaction between clinical centers, general practitioners
and associations of patients (Fig. 2).
This project represents the opportunity to build in
Italy a nationwide network of clinical and laboratory
centers sharing common diagnostic protocols in order to:
i) improve diagnosis and clinical management of patients
with genetic dyslipidemias; ii) promote the genetic
diagnosis; iii) increase awareness among physicians and
Fig. 1. Map of the location of clinical centers of LIPIGEN Network in Italy.
Fig. 2. Interaction between clinical centers, general practitioners and
associations of patients in the LIPIGEN program.
13M. Averna et al. / Atherosclerosis Supplements 29 (2017) 11e16patients; iv) create a national registry of FH, and v)
promote research activities in the field. To achieve these
objectives, the LIPIGEN steering committee started in
2012 a multicenter initiative, the LIPIGEN-FH study,focused on the most common genetic dyslipidemia,
familial hypercholesterolemia.
4. LIPIGEN-FH study
LIPIGEN-FH study is an observational, multicenter,
retrospective and prospective study, aimed at identifying
and registering patients with FH. LIPIGEN centers will also
focus their attention to other familial dyslipidemias; Table 1
shows the forms of dyslipidemias and their estimated
prevalence in Italy for which we are planning to build
specific registries.
Patients participating in the study do not undergo any
procedure other than normal clinical practice; clinical
variables that are collected for the study are those
commonly collected by physicians in daily clinical
practice.
The program has been approved by the Institutional
Review Board of the participating centers and conducted in
accordance with the principles of the Helsinki Declaration
(latest revision, October 2008), the standards of Good
Table 1
Estimated prevalence of primary dyslipidemias in Italy.
Dylipidemia Expected cases
Familial hypercholesterolemia 230,000
Type III hyperlipidemia 10,000 (?)
Severe hypertriglyceridemia 200 (?)
Familial hypertriglyceridemia ?
Familial hypobetalipoproteinemia 20,000
Familial combined hypolipidemia ?
Abetalipoproteinemia & chylomicron retention disease 50e100
Familial hypoalphalipoproteinemia ?
Familial hyperalphalipoproteinemia ?
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other applicable regulations.
Patients with clinical suspicion of primary dyslipidemias
are referred for genetic testing of the appropriate candidate
genes at one of six molecular diagnostic laboratories
serving as nationwide DNA diagnostic centers.
The clinical diagnosis of familial hypercholesterolemia
is based on the Dutch Lipid Network score, which indicates
the probability of FH [1]. The DLCN criteria allow to select
out individuals/families with a definite or probable diag-
nosis of FH (DLCN  6) in whom molecular genetic
testing is strongly recommended.
Clinical centers will base the suspicion of other genetic
dyslipidemias (Table 1) on common and standardized clin-
ical criteria both for pediatric and adult patients that have
been set by a board of Italian lipidologists. The criteria are
available in a dedicated web page managed by the SISA
Foundation accessible by network members authentication.
Given the complexity of genetic testing, professionals at
each clinical center manage genetic counseling. This
includes an explanation of inheritance patterns, information
about genetic testing, including potential benefits, risks, and
potential for incidental or uncertain findings and once
results are obtained, genetic counselors should discuss the
results and interpretations of the genetic tests with patients
and test family members in case of positive results.
Clinical centers also discuss with patients with definite
clinical diagnosis who have no identifiable mutations (for
example in FH about 20e30%) the need of adherence to
treatments, follow-up visits and further genetic testing
modalities if required.5. Data collection
At first, the program has taken advantage of surveys
conducted with the aim of assessing the molecular bases
and the clinical features of familial dyslipidemias (ie, FH,
severe HTG, familial hypocholesterolemias) in a cohort of
patients attending Italian Lipid Clinics [10e13].
Patients of any age and sex with clinical suspicion of
familial dyslipidemias who are able to understand the study
procedures and who voluntarily agree to participate by
providing written informed consent specifically intendedfor adult and children, may be referred to LIPIGEN study
through 40 Italian clinical centers included in the network.
For each subject enrolled in the study, all available demo-
graphic and clinical data (for example age, details of past
medical history, family history, smoking status, alcohol
consumption) as well as information on medication both at
baseline and during follow-up visits were recorded in an
electronic Case Report Form (eCRF) platform.
From 2012 to October 2016, available biochemical and
clinical data of 3480 subjects were included in the data-
base; 56.1% of them had a DLCN score 6, 23.6% had
a score between 6 and 8 (probable FH) and 32.5% a score
>8 (definite FH). Preliminary data analysis revealed that
tendon xanthomas and corneal arc were observed in 21.8%
and in 8.8% of cases respectively, family history of
premature coronary events was reported in 38.8% and the
personal history of premature coronary artery disease or of
stroke and peripheral vascular disease had a prevalence of
11.3% and 9.6% respectively.
Genetic analysis has been performed in 97.8% of
subjects with a mutation detection rate of 92.0% in patients
with a DLCN score 6; more than 98% of patients with
genetic diagnosis were carriers of mutations in the LDL
receptor (LDLR) gene and 49 (1.7%) were true homozy-
gous, 46 (1.6%) compound heterozygotes and 28 (1.0%)
double heterozygous.
The inclusion of data of index cases and affected and
unaffected relatives will contribute to build for the first time
in Italy the register of familial hypercholesterolemia. Similar
studies will follow for the other genetic dyslipidemias.
6. Conclusions
Identification and management of patients with familial
dyslipidemias remain a challenge. The robust numbers
coming from the experience of the Netherlands stress the
value of registries for the early identification and clinical
management of patients with familial hypercholesterolemia.
The LIPIGEN network is aimed at identifying and
registering patients with FH and other familial dyslipide-
mias in Italy. The consortium of clinical centers should
uniform definition of the clinical diagnosis and promote
a nationwide systematic approach to identify patients with
familial dyslipidemias and promote genetic cascade testing.
We are aware it will be a continuous task to organize
a country-wide program for the screening and identification
of patients with a wide range of familial disorders but we
are convinced that the establishment of national diseases
registers will have important effects on clinical manage-
ment and will improve knowledge of the natural history of
the diseases and the effect of treatments, including the
evaluation of innovative therapies and their follow-up.
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